John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$254M |
| 2 |
Bank of America
BAC
|
+$228M |
| 3 |
KLA
KLAC
|
+$205M |
| 4 |
TSMC
TSM
|
+$191M |
| 5 |
CVS Health
CVS
|
+$182M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.06B |
| 2 |
Meta Platforms (Facebook)
META
|
+$254M |
| 3 |
Goldman Sachs
GS
|
+$237M |
| 4 |
Amazon
AMZN
|
+$229M |
| 5 |
PayPal
PYPL
|
+$212M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.63% |
| 2 | Healthcare | 13.66% |
| 3 | Financials | 12.92% |
| 4 | Industrials | 10.81% |
| 5 | Consumer Discretionary | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2876
KALA BIO
KALA
$15.5M
| $79.8K | ﹤0.01% |
+280
| New | +$88.3K |
|
2877
TScan Therapeutics
TCRX
$52.8M
| $78.4K | ﹤0.01% |
+15,745
| New | +$95K |
|
|
GRTS
2878
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $77.3K | ﹤0.01% |
+133,261
| New | +$74.7K |
|
2879
Ceragon Networks
CRNT
$188M
| $77.3K | ﹤0.01% |
+28,200
| New | +$77.1K |
|
|
KRON
2880
DELISTED
Kronos Bio
KRON
| $76.6K | ﹤0.01% |
76,618
-4,762
| -6% | -$5.27K |
|
2881
China Automotive Systems
CAAS
$145M
| $76.2K | ﹤0.01% |
16,562
-1,747
| -10% | -$6.53K |
|
2882
PetMed Express
PETS
$37.9M
| $75K | ﹤0.01% |
20,389
-39,284
| -66% | -$139K |
|
2883
Riskified
RSKD
$779M
| $74.6K | ﹤0.01% |
15,779
-48
| -0.3% | -$262 |
|
|
TVRD
2884
Tvardi Therapeutics
TVRD
$23.7M
| $74.2K | ﹤0.01% |
6,692
-368
| -5% | -$4.31K |
|
|
AGIG
2885
Abundia Global Impact Group
AGIG
$41.5M
| $73.7K | ﹤0.01% |
6,698
+606
| +10% | +$7.09K |
|
|
NOTV
2886
DELISTED
Inotiv
NOTV
| $72.6K | ﹤0.01% |
42,724
-109,054
| -72% | -$184K |
|
|
LYRA
2887
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $72.6K | ﹤0.01% |
5,651
-4,166
| -42% | -$61.2K |
|
2888
Imperial Petroleum
IMPP
$236M
| $72.2K | ﹤0.01% |
17,391
+960
| +6% | +$3.79K |
|
2889
Monte Rosa Therapeutics
GLUE
$1.16B
| $71.5K | ﹤0.01% |
+13,500
| New | +$68.1K |
|
2890
Karyopharm Therapeutics
KPTI
$42.9M
| $71.3K | ﹤0.01% |
5,729
+4,805
| +520% | +$59.7K |
|
|
CLLS
2891
Cellectis
CLLS
$326M
| $70.8K | ﹤0.01% |
33,412
-6,877
| -17% | -$14.9K |
|
2892
Babcock & Wilcox
BW
$1.17B
| $70.5K | ﹤0.01% |
34,557
-112,898
| -77% | -$160K |
|
2893
Gevo
GEVO
$376M
| $69.7K | ﹤0.01% |
+42,778
| New | +$34.7K |
|
2894
Wrap Technologies
WRAP
$90.2M
| $69.4K | ﹤0.01% |
46,260
-6,228
| -12% | -$10.1K |
|
2895
Passage Bio
PASG
$14.1M
| $68.6K | ﹤0.01% |
4,902
-291
| -6% | -$4.63K |
|
2896
AEON Biopharma
AEON
$9.78M
| $68.5K | ﹤0.01% |
+906
| New | +$79.7K |
|
|
ADAM
2897
Adamas Trust
ADAM
$891M
| $68.4K | ﹤0.01% |
+10,809
| New | +$69.6K |
|
2898
Smart Sand
SND
$199M
| $68.3K | ﹤0.01% |
34,662
-5,537
| -14% | -$11.4K |
|
2899
Lifezone Metals Ltd Warrants
LZM.WS
$36.4M
| $68.2K | ﹤0.01% |
+104,899
| New | +$66.1K |
|
2900
Hyperfine
HYPR
$92.4M
| $67.9K | ﹤0.01% |
62,902
-7,851
| -11% | -$8.37K |
|
Similar funds
John Overdeck's Q3 2024 Portfolio in Review
As of Q3 2024, John Overdeck held 3,433 positions worth $45.6B, up 3.9% from $43.9B the previous quarter. Its ten largest holdings account for 6.6% of the portfolio.
John Overdeck withdrew a net $1.83B in Q3 2024, closing 348 positions and reducing 1,306 holdings. Its most notable exit was Intel, an estimated $161M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, John Overdeck opened a new position in Bank of America worth $226M.
- John Overdeck's largest Q3 2024 buy was Bank of America: 5,683,991 shares worth $226M.
- John Overdeck added most to Alphabet (Google) Class A in Q3 2024, an estimated $254M increase.
- John Overdeck's biggest Q3 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.06B.
- John Overdeck fully exited Intel in Q3 2024, selling an estimated $161M.
- John Overdeck's ten largest holdings make up 6.6% of its $45.6B portfolio in Q3 2024.
- John Overdeck opened 444 new positions and closed 348 in Q3 2024.
- John Overdeck's portfolio value rose 3.9% quarter-over-quarter to $45.6B.
Based on Two Sigma Investments's 13F filing for Q3 2024, filed 14 Nov 2024.